# Bicycle Therapeutics plc: financial statements, quarterly

BCYC · Nasdaq · CIK 1761612 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bcyc.md) · [Financials](/companies/bcyc/financials.md) · [Filings](/companies/bcyc/filings.md) · [Insiders](/companies/bcyc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bcyc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5.3 d](/filings/0001104659-26-028971.md) | [19.5](/filings/0001558370-25-006049.md) | [9.4](/filings/0001558370-25-010843.md) | [2.7](/filings/0001104659-25-104010.md) | [3.7 d](/filings/0001104659-26-028971.md) | [10.0](/filings/0001104659-26-052117.md) | [2.9](/filings/0001104659-26-088457.md) | [11.7](/filings/0001104659-26-119864.md) | [48.0 d](/filings/0001104659-26-028971.md) | [0.9](/filings/0001104659-26-052117.md) | [0.6](/filings/0001104659-26-088457.md) | [34.1](/filings/0001104659-26-119864.md) |
| Research and development | $m | [44.7 d](/filings/0001104659-26-028971.md) | [34.9](/filings/0001558370-25-006049.md) | [40.1](/filings/0001558370-25-010843.md) | [48.3](/filings/0001104659-25-104010.md) | [49.8 d](/filings/0001104659-26-028971.md) | [59.1](/filings/0001104659-26-052117.md) | [71.0](/filings/0001104659-26-088457.md) | [58.4](/filings/0001104659-26-119864.md) | [51.8 d](/filings/0001104659-26-028971.md) | [48.9](/filings/0001104659-26-052117.md) | [41.2](/filings/0001104659-26-088457.md) | [33.4](/filings/0001104659-26-119864.md) |
| Operating income | $m | [(54.2) d](/filings/0001104659-26-028971.md) | [(31.7)](/filings/0001558370-25-006049.md) | [(46.6)](/filings/0001558370-25-010843.md) | [(63.8)](/filings/0001104659-25-104010.md) | [(67.7) d](/filings/0001104659-26-028971.md) | [(70.2)](/filings/0001104659-26-052117.md) | [(86.6)](/filings/0001104659-26-088457.md) | [(65.6)](/filings/0001104659-26-119864.md) | [(24.7) d](/filings/0001104659-26-028971.md) | [(65.5)](/filings/0001104659-26-052117.md) | [(54.6)](/filings/0001104659-26-088457.md) | [(13.5)](/filings/0001104659-26-119864.md) |
| Interest expense | $m | [0.8 d](/filings/0001558370-24-001324.md) | [0.8](/filings/0001558370-24-006453.md) | [0.8](/filings/0001558370-25-010843.md) | [0.0](/filings/0001104659-25-104010.md) | [0.1 d](/filings/0001104659-26-028971.md) | [0.1](/filings/0001104659-26-052117.md) | [0.1](/filings/0001104659-26-088457.md) | [0.0](/filings/0001104659-26-119864.md) | [0.1 d](/filings/0001104659-26-028971.md) | [0.0](/filings/0001104659-26-052117.md) | [0.0](/filings/0001104659-26-088457.md) | [0.0](/filings/0001104659-26-119864.md) |
| Income tax | $m | [0.3 d](/filings/0001104659-26-028971.md) | [(0.4)](/filings/0001558370-25-006049.md) | [0.1](/filings/0001558370-25-010843.md) | [(3.4)](/filings/0001104659-25-104010.md) | [(1.1) d](/filings/0001104659-26-028971.md) | [(1.1)](/filings/0001104659-26-052117.md) | [(0.2)](/filings/0001104659-26-088457.md) | [0.2](/filings/0001104659-26-119864.md) | [1.3 d](/filings/0001104659-26-028971.md) | [0.2](/filings/0001104659-26-052117.md) | [0.1](/filings/0001104659-26-088457.md) | [1.2](/filings/0001104659-26-119864.md) |
| Net income | $m | [(49.1) d](/filings/0001104659-26-028971.md) | [(26.6)](/filings/0001104659-25-104010.md) | [(39.8)](/filings/0001104659-25-104010.md) | [(50.8)](/filings/0001104659-25-104010.md) | [(51.9) d](/filings/0001104659-26-028971.md) | [(60.8)](/filings/0001104659-26-119864.md) | [(79.0)](/filings/0001104659-26-119864.md) | [(59.1)](/filings/0001104659-26-119864.md) | [(20.2) d](/filings/0001104659-26-028971.md) | [(60.8)](/filings/0001104659-26-119864.md) | [(50.3)](/filings/0001104659-26-119864.md) | [(10.5)](/filings/0001104659-26-119864.md) |
| Diluted EPS | $ per share | not reported | [(0.62)](/filings/0001558370-25-006049.md) | [(0.77)](/filings/0001558370-25-010843.md) | [(0.74)](/filings/0001104659-25-104010.md) | not reported | [(0.88)](/filings/0001104659-26-052117.md) | [(1.14)](/filings/0001104659-26-088457.md) | [(0.85)](/filings/0001104659-26-119864.md) | not reported | [(0.87)](/filings/0001104659-26-052117.md) | [(0.72)](/filings/0001104659-26-088457.md) | [(0.15)](/filings/0001104659-26-119864.md) |
| Basic EPS | $ per share | not reported | [(0.62)](/filings/0001558370-25-006049.md) | [(0.77)](/filings/0001558370-25-010843.md) | [(0.74)](/filings/0001104659-25-104010.md) | not reported | [(0.88)](/filings/0001104659-26-052117.md) | [(1.14)](/filings/0001104659-26-088457.md) | [(0.85)](/filings/0001104659-26-119864.md) | not reported | [(0.87)](/filings/0001104659-26-052117.md) | [(0.72)](/filings/0001104659-26-088457.md) | [(0.15)](/filings/0001104659-26-119864.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [526](/filings/0001104659-26-028971.md) | [457](/filings/0001558370-25-006049.md) | [961](/filings/0001558370-25-010843.md) | [891](/filings/0001104659-25-104010.md) | [880](/filings/0001104659-26-028971.md) | [793](/filings/0001104659-26-052117.md) | [721](/filings/0001104659-26-088457.md) | [648](/filings/0001104659-26-119864.md) | [628](/filings/0001104659-26-119864.md) | [559](/filings/0001104659-26-052117.md) | [510](/filings/0001104659-26-088457.md) | [470](/filings/0001104659-26-119864.md) |
| Current assets | $m | [562](/filings/0001558370-25-001438.md) | [516](/filings/0001558370-24-006453.md) | [1,028](/filings/0001558370-24-010949.md) | [966](/filings/0001558370-24-014004.md) | [929](/filings/0001104659-26-028971.md) | [856](/filings/0001558370-25-006049.md) | [804](/filings/0001558370-25-010843.md) | [739](/filings/0001104659-25-104010.md) | [683](/filings/0001104659-26-119864.md) | [619](/filings/0001104659-26-052117.md) | [575](/filings/0001104659-26-088457.md) | [538](/filings/0001104659-26-119864.md) |
| Total assets | $m | [595](/filings/0001558370-25-001438.md) | [547](/filings/0001558370-24-006453.md) | [1,057](/filings/0001558370-24-010949.md) | [997](/filings/0001558370-24-014004.md) | [957](/filings/0001104659-26-028971.md) | [884](/filings/0001558370-25-006049.md) | [832](/filings/0001558370-25-010843.md) | [764](/filings/0001104659-25-104010.md) | [718](/filings/0001104659-26-119864.md) | [652](/filings/0001104659-26-052117.md) | [607](/filings/0001104659-26-088457.md) | [567](/filings/0001104659-26-119864.md) |
| Current liabilities | $m | [69.5](/filings/0001558370-25-001438.md) | [49.5](/filings/0001558370-24-006453.md) | [69.6](/filings/0001558370-24-010949.md) | [56.4](/filings/0001558370-24-014004.md) | [67.2](/filings/0001104659-26-028971.md) | [57.6](/filings/0001558370-25-006049.md) | [77.4](/filings/0001558370-25-010843.md) | [69.3](/filings/0001104659-25-104010.md) | [57.0](/filings/0001104659-26-119864.md) | [48.9](/filings/0001104659-26-052117.md) | [47.6](/filings/0001104659-26-088457.md) | [44.5](/filings/0001104659-26-119864.md) |
| Total liabilities | $m | [224](/filings/0001558370-25-001438.md) | [191](/filings/0001558370-24-006453.md) | [184](/filings/0001558370-24-010949.md) | [166](/filings/0001558370-24-014004.md) | [164](/filings/0001104659-26-028971.md) | [144](/filings/0001558370-25-006049.md) | [163](/filings/0001558370-25-010843.md) | [145](/filings/0001104659-25-104010.md) | [108](/filings/0001104659-26-119864.md) | [98.1](/filings/0001104659-26-052117.md) | [96.3](/filings/0001104659-26-088457.md) | [61.9](/filings/0001104659-26-119864.md) |
| Long-term debt | $m | [30.7](/filings/0001558370-25-001438.md) | [30.8](/filings/0001558370-24-006453.md) | [8.5](/filings/0001558370-24-010949.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | [22.4](/filings/0001558370-24-010949.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [371](/filings/0001104659-26-028971.md) | [356](/filings/0001104659-25-104010.md) | [874](/filings/0001104659-25-104010.md) | [831](/filings/0001104659-25-104010.md) | [793](/filings/0001104659-26-119864.md) | [740](/filings/0001104659-26-119864.md) | [669](/filings/0001104659-26-119864.md) | [618](/filings/0001104659-26-119864.md) | [610](/filings/0001104659-26-119864.md) | [554](/filings/0001104659-26-119864.md) | [510](/filings/0001104659-26-119864.md) | [505](/filings/0001104659-26-119864.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(47.3) d](/filings/0001104659-26-028971.md) | [(70.9)](/filings/0001558370-25-006049.md) | [(44.6) d](/filings/0001558370-25-010843.md) | [(39.8) d](/filings/0001104659-25-104010.md) | [(9.4) d](/filings/0001104659-26-028971.md) | [(86.4)](/filings/0001104659-26-052117.md) | [(72.8) d](/filings/0001104659-26-088457.md) | [(71.2) d](/filings/0001104659-26-119864.md) | [(19.3) d](/filings/0001104659-26-028971.md) | [(65.9)](/filings/0001104659-26-052117.md) | [(49.6) d](/filings/0001104659-26-088457.md) | [(40.3) d](/filings/0001104659-26-119864.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001104659-26-028971.md) | [0.0](/filings/0001558370-25-006049.md) | [0.4 d](/filings/0001558370-25-010843.md) | [0.4 d](/filings/0001104659-25-104010.md) | [0.4 d](/filings/0001104659-26-028971.md) | [0.6](/filings/0001104659-26-052117.md) | [0.5 d](/filings/0001104659-26-088457.md) | [0.7 d](/filings/0001104659-26-119864.md) | [0.6 d](/filings/0001104659-26-028971.md) | [0.7](/filings/0001104659-26-052117.md) | [0.3 d](/filings/0001104659-26-088457.md) | [0.3 d](/filings/0001104659-26-119864.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.0](/filings/0001558370-24-006453.md) | [30.2](/filings/0001558370-24-010949.md) | [39.6](/filings/0001558370-24-014004.md) | [42.6](/filings/0001558370-25-006049.md) | [52.0](/filings/0001558370-25-010843.md) | [69.0](/filings/0001104659-25-104010.md) | [69.2](/filings/0001104659-26-052117.md) | [69.3](/filings/0001104659-26-088457.md) | [69.3](/filings/0001104659-26-119864.md) | [69.7](/filings/0001104659-26-052117.md) | [69.8](/filings/0001104659-26-088457.md) | [70.0](/filings/0001104659-26-119864.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,043,486 at 2023-05-01, from the cover of the [10-Q filed 2023-05-04](/filings/0001558370-23-007979.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 07:25 ET. No prices; not investment advice.